Press Release

Human Insulin Market to Grow at a Steady CAGR until 2025

Growing diabetic population to drive global human insulin market during forecast period

According to TechSci Research report, Global Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Brand (Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Others), By Products (Insulin Pens, Insulin Pumps, Others), By Region, Forecast & Opportunities, 2025”, global market for human insulin is anticipated to grow at a steady CAGR during the forecast period.  Increasing number of diabetic patients across globe is contributing to the increasing demand for human insulin to control the blood sugar levels in the body. Diabetes is a chronic disorder which further makes the body prone to many more diseases, thus it is quite important to handle the glucose levels of the body in an efficient way. In the past few years, diabetes has not only been limited to the geriatric population, but young population is equally prone to diabetes. Technology advancements and urbanization have resulted in reduced physical activities which are required for a healthy body. This kind of unhealthy lifestyle makes people prone to obesity, diabetes and many other chronic diseases; consequently, driving the human insulin market, globally. However, the complexity and the expensiveness of the product might restrain the market as every diabetic patient might not be able to afford human insulin and hence, shifts to conventional medicines.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on " Global Human Insulin Market"

https://www.techsciresearch.com/report/human-insulin-market/4637.html

The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products and region. Based on indication, global human insulin market can be segregated into type I diabetes and type II diabetes. Out of these, type II is projected to account for the lion’s share during the forecast period as roughly 90% of the population across the world suffers from type II diabetes.

Some of the leading players in global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk, Physicians Total Care, Inc., Eli Lilly and Company, A-S Medication Solutions, REMEDYREPACK INC., Sedico Co., Sanofi Aventis, Pfizer Inc., PerkinElmer, Merck, Biocon, Wockhardt, Julphal, Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter, Tandem Diabetes Care, Inc., etc. In order to expand their market share, the companies adopt various strategies including organic and inorganic like mergers & acquisition. For instance, Eli Lilly and Boehringer Ingelheim GmbH, the two renowned biotech & pharma companies in the healthcare sector have joined hands to develop Basaglar (Insulin Glargine) for better and advanced treatment of diabetic patients.

Download Sample Report https://www.techsciresearch.com/sample-report.aspx?cid=4637

Customers can also request for 10% free customization on this report.

“In terms of regional analysis, North America dominated the global human insulin market in 2019 due to increasing cases of diabetes in countries like United States and Canada. However, Asia-Pacific region is expected the fastest growing region as it comprises of countries like China and India which have high prediabetic and diabetic population. Additionally, rising awareness pertaining to the use of human insulin in diabetes and strong distribution network of leading product manufacturers is anticipated to positively impact the growth of the market in the region.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

Global Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Brand (Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Others), By Products (Insulin Pens, Insulin Pumps, Others), By Region, Forecast & Opportunities, 2025”, has evaluated the future growth potential of global human insulin market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global human insulin market.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Relevant News